Methotrexate in rheumatoid arthritis. a five-year prospective multicenter study
| Autor: | Bernard F. Germain, Dennis Torretti, Larry J. Anderson, Herbert Kaplan, Sheldon D. Solomon, Barbara N. Weissman, Frederick Wolfe, Eric P. Gall, Michael E. Weinblatt, Richard C. Merriman, Sidney R. Block, Bruce Wall |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Immunology Arthritis Severity of Illness Index law.invention Arthritis Rheumatoid Rheumatology Randomized controlled trial law Internal medicine medicine Humans Immunology and Allergy Pharmacology (medical) Prospective Studies skin and connective tissue diseases Prospective cohort study Aged Aged 80 and over medicine.diagnostic_test business.industry Middle Aged medicine.disease Surgery Clinical trial Methotrexate Treatment Outcome Tolerability Joint pain Rheumatoid arthritis Erythrocyte sedimentation rate Prednisone Female medicine.symptom business Follow-Up Studies |
| Zdroj: | Arthritis & Rheumatism. 37:1492-1498 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.1780371013 |
| Popis: | Objective. To evaluate the efficacy and tolerability of oral methotrexate (MTX) in rheumatoid arthritis (RA) in a long-term prospective trial. Methods. One hundred twenty-three patients with RA who completed a 9-month multicenter randomized trial comparing MTX and auranofin enrolled in this 5-year prospective study of MTX. Results. Significant (P = 0.0001) improvement compared with baseline was noted in all clinical disease variables, functional status, and the Westergren erythrocyte sedimentation rate (ESR). “Marked improvement” occurred in 87 (71%) and 85 (69%) of the patients, respectively, in the joint pain/tenderness index and the joint swelling index at the last evaluable visit. Forty-four patients (36%) withdrew during the study. Eight (7%) withdrew due to lack of efficacy, and 8 (7%) due to adverse experiences, including 1 patient with cirrhosis. At 5 years, 64% of patients were still taking MTX and completed the study. Conclusion. This large prospective study of long-term MTX treatment demonstrates sustained clinical response and improvement in the Westergren ESR and functional assessment scores, with an acceptable toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text